Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM TrialMarcello Tiseo, Andrea Ardizzoni, Luca Boni et al.|Journal of Clinical Oncology|2017Cited by 186
The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female PowerEnrico Franceschi, Anna Maria Cremonini, Alicia Tosoni et al.|World Neurosurgery|2018Cited by 59
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)Francesco Gelsomino, Andrea Ardizzoni, Marcello Tiseo et al.|British Journal of Cancer|2020Cited by 25
Italian Multicenter Phase III Randomized Study of Cisplatin–Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM TrialMarcello Tiseo, Andrea Ardizzoni, Luca Boni et al.|Clinical Lung Cancer|2014Cited by 19
Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trial.Marcello Tiseo, Andrea Ardizzoni, Luca Boni et al.|Journal of Clinical Oncology|2016Cited by 2